Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S408 gov, NCT03755804) consented to pharmacokinetic testing and had blood samples obtained during either cycle 1 (n=4) or cycle 2 (n=16). Interventions: Bendamustine was substituted for mechlorethamine in the Stanford V backbone due to the unavailability of mechlorethamine. Low-risk patients received 2 cycles of BEABOVP therapy while intermediate-risk patients received 3 cycles. Treatment cycles were 28 days in length. Bendamustine 180 mg/m2 was given intravenously (IV) over 1 hour on Day 1 of each cycle. Main Outcome Measures: This analysis includes 118 bendamustine plasma concentrations from 20 individuals who received a single daily dose of 180 mg/m2 bendamustine. Results: Patients ranged in age from 4.9 to 21.4 years. Bendamustine concentration-vstime data demonstrated a trend toward decreasing clearance with increasing age (P=0.074) and age explained 23% of the interindividual variability in clearance. The median (range) AUC was 12,415 (8,539–18,642) µg hr/L and the median (range) maximum bendamustine concentration was 11,708 (8,034–15,741) µg/L. The regimen was well tolerated with no grade 3 toxicities resulting in treatment delays of more than 7 days. Conclusions: A single-day dose of 180 mg/m2 of bendamustine every 28 days was safe and well tolerated in pediatric patients with HL receiving BEABOVP therapy. Age accounted for 23% of inter-individual variability observed in bendamustine clearance. Keywords: lymphoma, combination therapy, Hodgkin lymphoma, HL, bendamustine, chemotherapy HL-122 Microbiota Changes in Hodgkin and Non‑Hodgkin Lymphoma Treatment: Assessment With Il‑17 and Il‑12 Levels Ekin Ece Gürer MD1, Sevgi Kalayoğlu Beşışık MD2, Uğur Sezerman MD3, Zerrin Aktaş MD4, Fatma Savran Oğuz MD1, Tarık Onur Tiryaki MD2, Durdan Serap Kuruca MD5, Gülsen Günel MD4, Fatma Erdem MD6, Mustafa Oral Öncül MD7 1Faculty of Medicine, Department of Medical Biology, Istanbul University, Istanbul, Turkey. 2Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, Istanbul, Turkey. 3Faculty of Medicine, Department of Biostatistics and Medical Informatics, Acibadem University, Istanbul, Turkey. 4Faculty of Medicine, Department of Clinical Microbiology, Istanbul University, Istanbul, Turkey. 5Faculty of Medicine, Department of Physiology, Istanbul University, Istanbul, Turkey. 6Faculty of Medicine, Department of Microbiology, Eskişehir Osmangazi University, Eskişehir, Turkey. 7Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul University, Istanbul, Turkey Objective: This study aimed to document changes in microbiota and cytokine (IL-12, IL-17) levels during chemotherapy in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) and assess their potential impact on treatment outcomes. Methodology: Stool samples were collected before chemotherapy and after the third course from 30 patients. Alpha diversity of the microbiota was calculated using R Statistical Computer Language, and statistical analyses were performed to identify significant changes. Expression levels of IL-12 and IL-17 were evaluated using rtPCR. The study utilized R Statistical Computer Language and Rstudio IDE for data analysis and visualization. Microbiota composition and diversity were assessed using OTU tables, and cytokine levels were measured through rtPCR. Results: In HL patients, the Coproccocus genus significantly increased after treatment, while Clostridia UCG1, Romboutsia, and Akkermansia decreased. Metabolic pathways related to D-arginine, D-ornithine metabolism, glycosaminoglycan degradation, glycosphingolipid biosynthesis ganglio series, and sesquiterpenoid and triterpenoid biosynthesis showed decreased activity. In NHL patients, the nitrotoluene degradation pathway exhibited decreased activation, while the apoptosis multiple species pathway showed increased activation following treatment. Conclusion: The diversity of the gut microbiota is unique to each individual and remains relatively stable throughout adult life. However, chemotherapy can disrupt the balance of the microbiota, leading to dysbiosis. Microbiota composition has been implicated in tumorigenesis and may also influence the response to chemotherapy. Understanding the baseline microbiota profile before chemotherapy could help tailor treatment regimens to modify gut dysbiosis during chemotherapy and potentially enhance treatment response. Further research is needed to explore the role of the microbiota in anticancer therapies and develop strategies to modulate the microbiota to improve treatment outcomes in lymphoma patients. Keywords: HL, Hodgkin lymphoma, NHL, non-Hodgkin lymphoma, microbiota HL-214 Breast Pleomorphic Liposarcoma in a Case With a History of Hodgkin Lymphoma Amr Abouzid MD1, Shaimaa M Yussif MD2, May Denewer MD1 1Oncology Center, Mansoura University, Mansoura, Egypt. 2Faculty of Medicine, Mansoura University, Mansoura, Egypt Context: Breast sarcoma is an uncommon mesenchymal neoplasm of the breast and constitutes <1% of all malignant breast neoplasms and <5% of all sarcomas. According to Surveillance, Epidemiology, and End Results (SEER) data, the breast sarcoma annual incidence rate is 4.6 cases per 1,000,000 women. Objective: We report a case with right breast pleomorphic liposarcoma after receiving chest wall radiotherapy for Hodgkin lymphoma (HL). Design: This case was diagnosed and observed in April 2018 until now. Setting: Department of Surgical Oncology, Oncology Center, Mansoura University, Egypt. Patient: We are reporting on a 23-year-old female patient with a history of HL who presented in April 2021 to the Department of Surgical Oncology, Oncology Center, Mansoura University with a right breast pleomorphic liposarcoma. This patient was diagnosed with HL in April 2018 by core needle biopsy from a right-sided neck swelling and an amalgamated mediastinal lymph node sized 14.7 cm SUV max 16.7 by positron emission tomography/computed tomography (PET/ CT) scan. This patient received 6 cycles of ABVD protocol and LDIFRTH 30GR/15FR. The following-up PET/CT scan was free. The patient developed a right breast lump in April 2021 sized 32 mm and BIRADs IV by breast US and breast MRI. Interventions: A
RkJQdWJsaXNoZXIy MTk3NTQxMg==